ESR Essentials: diagnosis and assessment of treatment response in patients with luminal Crohn’s disease—practice recommendations by the European Society of Gastrointestinal and Abdominal Radiology - Scorecard - MDSpire
Advertisement
ESR Essentials: diagnosis and assessment of treatment response in patients with luminal Crohn’s disease—practice recommendations by the European Society of Gastrointestinal and Abdominal Radiology
Clinical Scorecard: Key Insights on ESR: Evaluating Diagnosis and Treatment Response in Luminal Crohn’s Disease—Guidelines from the European Society of Gastrointestinal and Abdominal Radiology
At a Glance
Category
Detail
Condition
Luminal Crohn’s Disease (CD), a lifelong relapsing and remitting inflammatory bowel disease affecting any part of the gastrointestinal tract
Key Mechanisms
Patchy transmural inflammation involving genetic, environmental, immune factors, and gut microbiome interactions
Target Population
Patients with suspected or diagnosed luminal Crohn’s Disease requiring diagnosis, phenotyping, and treatment response assessment
Care Setting
Gastroenterology and radiology multidisciplinary teams in outpatient and acute care settings
Key Highlights
Cross-sectional imaging (MR Enterography and intestinal ultrasound) is central to diagnosis, phenotyping, and monitoring treatment response in luminal CD.
Imaging signs of active disease include bowel mural thickening, mural and perimural oedema, ulceration, and hypervascularity, often superimposed on chronic changes.
Structured reporting using standardized terminology per ECCO-ESGAR recommendations improves multidisciplinary communication and treatment decisions.
Guideline-Based Recommendations
Diagnosis
Use MR Enterography (MRE) as the preferred imaging modality for initial diagnosis and staging due to superior sensitivity and specificity, especially for ileal disease.
Intestinal ultrasound (IUS) is a useful first-line, well-tolerated, and accurate alternative for detecting small bowel CD.
Reserve CT imaging for acute or emergency settings or when non-ionising imaging is unavailable.
Management
Classify disease phenotype into inflammatory, stricturing, or penetrating subtypes to guide management strategies.
Adopt a treat-to-target approach with regular objective assessment of disease activity using cross-sectional imaging.
Express treatment response according to ECCO-ESGAR categories: transmural remission, significant transmural response, stable disease, or progressive disease with/without complications.
Monitoring & Follow-up
Use cross-sectional imaging modalities to assess treatment response and detect complications beyond mucosal evaluation.
Implement standardized imaging acquisition protocols and structured reporting to ensure consistency and clarity.
Regularly reassess disease activity and phenotype to optimize therapeutic decisions.
Risks
Limit CT use due to ionising radiation exposure, especially in younger patients and for repeated assessments.
Recognize that symptoms may not correlate with inflammatory burden; rely on objective imaging findings for accurate disease monitoring.
Patient & Prescribing Data
Patients with luminal Crohn’s Disease undergoing diagnosis and treatment monitoring
Cross-sectional imaging guides personalized treatment by accurately defining disease extent, activity, and phenotype, facilitating treat-to-target strategies and early detection of complications.
Clinical Best Practices
Employ MR Enterography as the primary imaging modality for comprehensive small bowel evaluation at diagnosis.
Use intestinal ultrasound as a sensitive, non-invasive first-line tool for initial assessment and follow-up.
Apply standardized nomenclature and structured reporting per ESGAR and ECCO-ESGAR guidelines to enhance multidisciplinary communication.
Integrate imaging findings with clinical, biochemical, endoscopic, and histological data for holistic patient management.
Adopt a proactive treat-to-target approach focusing on objective disease control rather than symptom management alone.
